Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM4XMF7)

Drug Name
LY2606368 Drug Info
Synonyms
prexasertib; Prexasertib; 1234015-52-1; UNII-820NH671E6; LY-2606368; 820NH671E6; Prexasertib [USAN]; 5-((5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; 5-({5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl}amino)pyrazine-2-carbonitrile; 5-[[5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile; SCHEMBL1975451; GTPL9549; SCHEMBL19457660; SCHEMBL18989301; CHEMBL3544911; EX-A758; DOTGPNHGTYJDEP-UHFFFAOYSA-N; AOB87325; ZINC95837013
Cross-matching ID
PubChem CID
46700756
ChEBI ID
CHEMBL3544911
CAS Number
CAS 1234015-52-1
TTD Drug ID
D08UUL

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
TNF signaling pathway 2.41 0.00e+0 103/112 (91.96%) NFKBIA;JUNB;CXCL2;...
IL-17 signaling pathway 2.38 0.00e+0 84/94 (89.36%) NFKBIA;CXCL8;CXCL2;...
NF-kappa B signaling pathway 2.25 0.00e+0 90/104 (86.54%) NFKBIA;RELB;CXCL8;...
Viral protein interaction with cytokine and cytokine re... 2.19 0.00e+0 84/100 (84%) CXCL8;CXCL2;CCL20;...
p53 signaling pathway 2.01 3.93e-3 63/73 (86.3%) CDKN1A;PMAIP1;DDB2;...
C-type lectin receptor signaling pathway 1.97 4.92e-3 93/104 (89.42%) NFKBIA;RELB;EGR3;...
Hepatitis B 1.93 5.62e-3 151/162 (93.21%) NFKBIA;CDKN1A;CXCL8;...
Cytosolic DNA-sensing pathway 1.91 4.92e-3 52/63 (82.54%) NFKBIA;NFKB1;IKBKE;...
Viral carcinogenesis 1.89 5.46e-3 149/203 (73.4%) NFKBIA;CDKN1A;PMAIP1;...
Small cell lung cancer 1.87 9.83e-3 90/92 (97.83%) NFKBIA;CDKN1A;BIRC3;...
Legionellosis 1.84 9.83e-3 51/57 (89.47%) NFKBIA;CXCL8;CXCL2;...
Osteoclast differentiation 1.81 1.39e-2 117/127 (92.13%) NFKBIA;RELB;JUNB;...
Transcriptional misregulation in cancer 1.81 1.36e-2 158/192 (82.29%) CDKN1A;CXCL8;ID2;...
RIG-I-like receptor signaling pathway 1.78 1.83e-2 64/70 (91.43%) NFKBIA;CXCL8;NFKB1;...
Tryptophan metabolism 1.78 1.77e-2 35/42 (83.33%) ALDH2;CYP1A1;KMO;...
NOD-like receptor signaling pathway 1.77 1.84e-2 145/181 (80.11%) NFKBIA;CXCL8;CXCL2;...
Rheumatoid arthritis 1.76 1.85e-2 78/93 (83.87%) CXCL8;CXCL2;FOS;...
Cytokine-cytokine receptor interaction 1.75 2.02e-2 246/295 (83.39%) CXCL8;CXCL2;CCL20;...
Apoptosis 1.73 2.38e-2 126/168 (75%) NFKBIA;PMAIP1;ATF4;...
Human T-cell leukemia virus 1 infection 1.72 2.36e-2 197/219 (89.95%) EGR1;NFKBIA;RELB;...
Cocaine addiction 1.72 2.29e-2 42/49 (85.71%) ATF4;FOSB;NFKB1;...
Kaposi sarcoma-associated herpesvirus infection 1.71 2.28e-2 172/193 (89.12%) NFKBIA;CDKN1A;CXCL8;...
Toll-like receptor signaling pathway 1.68 2.91e-2 94/104 (90.38%) NFKBIA;CXCL8;FOS;...
Amphetamine addiction 1.68 2.79e-2 57/69 (82.61%) ATF4;FOS;FOSB;...
Measles 1.67 2.87e-2 133/139 (95.68%) NFKBIA;FOS;TNFAIP3;...
Adipocytokine signaling pathway 1.67 2.76e-2 64/69 (92.75%) NFKBIA;PCK2;NFKB1;...
Alanine, aspartate and glutamate metabolism 1.65 3.06e-2 27/37 (72.97%) ASNS;ASS1;GOT1;...
Epstein-Barr virus infection 1.64 3.30e-2 189/202 (93.56%) NFKBIA;RELB;CDKN1A;...
Lipid and atherosclerosis 1.64 3.29e-2 190/215 (88.37%) NFKBIA;CXCL8;CXCL2;...
FoxO signaling pathway 1.62 3.83e-2 118/131 (90.08%) CDKN1A;PCK2;GADD45B;...
Wnt signaling pathway -1.63 4.29e-2 124/166 (74.7%) TLE2;CCND3;NFATC3;...
Bile secretion -1.65 3.45e-2 68/90 (75.56%) ATP1A3;ABCG5;RXRA;...
Adherens junction -1.66 3.41e-2 63/71 (88.73%) RAC2;CSNK2A1;PTPRF;...
Biosynthesis of unsaturated fatty acids -1.68 3.05e-2 21/27 (77.78%) HACD3;FADS2;FADS1;...
Steroid hormone biosynthesis -1.69 2.65e-2 43/61 (70.49%) CYP11A1;STS;AKR1C4;...
Melanogenesis -1.71 2.40e-2 74/101 (73.27%) FZD4;MAPK1;GNAQ;...
Mismatch repair -1.71 2.43e-2 22/23 (95.65%) RFC2;POLD2;POLD1;...
Homologous recombination -1.75 1.53e-2 35/41 (85.37%) ATM;RPA2;BABAM1;...
Drug metabolism -1.76 1.48e-2 78/151 (51.66%) FMO3;GSTT2;GSTM5;...
Porphyrin and chlorophyll metabolism -1.80 1.12e-2 23/43 (53.49%) BLVRB;CP;UGT2B4;...
Various types of N-glycan biosynthesis -1.80 1.13e-2 26/39 (66.67%) MGAT4A;HEXA;RPN1;...
Mucin type O-glycan biosynthesis -1.83 8.91e-3 20/36 (55.56%) GALNT7;GALNT3;GCNT3;...
Other types of O-glycan biosynthesis -1.88 5.82e-3 29/47 (61.7%) COLGALT1;C1GALT1C1;B4GALT2;...
Vitamin digestion and absorption -1.90 3.39e-3 17/24 (70.83%) ABCC1;SCARB1;MMACHC;...
Metabolism of xenobiotics by cytochrome P450 -1.97 2.04e-3 49/77 (63.64%) ADH7;CYP2C9;CBR1;...
Steroid biosynthesis -1.99 2.55e-3 19/20 (95%) HSD17B7;LBR;NSDHL;...
Pentose and glucuronate interconversions -2.00 3.39e-3 17/34 (50%) UGDH;AKR1B1;SORD;...
Retinol metabolism -2.05 0.00e+0 41/68 (60.29%) CYP3A7;CYP2C18;ADH7;...
DNA replication -2.09 0.00e+0 34/36 (94.44%) RFC2;POLD2;POLD1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SK-ES-1 CVCL_0627 Homo sapiens 1.11uM - 10uM 24H
Brain
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 1.11uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MDA-MB-468 CVCL_0419 Homo sapiens 1.11uM - 10uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
T-47D CVCL_0553 Homo sapiens 1.11uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SNU-407 CVCL_5004 Homo sapiens 1.11uM - 10uM 24H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 1.11uM - 10uM 24H
HEC-1-A CVCL_0293 Homo sapiens 1.11uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 1.11uM - 3.33uM 24H
HEC-265 CVCL_2929 Homo sapiens 1.11uM - 10uM 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CJM CVCL_U797 Homo sapiens 1.11uM - 3.33uM 24H
Liver
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHH-5 CVCL_1320 Homo sapiens 1.11uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1573 CVCL_1483 Homo sapiens 1.11uM - 10uM 24H
NCI-H838 CVCL_1594 Homo sapiens 1.11uM - 10uM 24H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 1.11uM - 10uM 24H
HCC95 CVCL_1276 Homo sapiens 1.11uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H2110 CVCL_1529 Homo sapiens 1.11uM - 10uM 24H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 1.11uM - 3.33uM 24H
Ovary
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVTOKO CVCL_3114 Homo sapiens 1.11uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 1.11uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
IGR-37 CVCL_1303 Homo sapiens 1.11uM - 10uM 24H
Mel-HO CVCL_1402 Homo sapiens 1.11uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 1.11uM - 10uM 24H
Urinary bladder
Bladder carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BC-3C CVCL_1079 Homo sapiens 1.11uM - 10uM 24H
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 3.33uM - 10uM 24H